INS and type 2 diabetes mellitus: Due to specially intimate relationship between brain insulin resistance and AD, and the relative “paralysis” of brain insulin signaling through the IRS-1 → AKT pathway in mild MCI and AD, there are voices suggesting that restoring signaling through this pathway with therapeutic agents originally developed for the treatment of T2DM, may be of particular benefit.